000			02039 a2200541 4500
005			20250517222058.0
264		0	_c20191028
008			201910s 0 0 eng d
022			_a2379-3708
024	7		_a10.1172/jci.insight.120626 _2doi
040			_aNLM _beng _cNLM
100	1		_aLim, Ee Lyn
245	0	0	_aPhosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. _h[electronic resource]
260			_bJCI insight _c06 2018
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnimals
650	0	4	_aAntigens, Neoplasm _xadministration & dosage
650	0	4	_aAntineoplastic Agents, Immunological _xpharmacology
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology
650	0	4	_aCancer Vaccines _xpharmacology
650	0	4	_aCell Line, Tumor _xtransplantation
650	0	4	_aClass I Phosphatidylinositol 3-Kinases
650	0	4	_aCostimulatory and Inhibitory T-Cell Receptors _xantagonists & inhibitors
650	0	4	_aDiphtheria Toxin _xadministration & dosage
650	0	4	_aDisease Models, Animal
650	0	4	_aDrug Interactions
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLymphocyte Depletion _xmethods
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aPhosphatidylinositol 3-Kinases _ximmunology
650	0	4	_aPhosphoinositide-3 Kinase Inhibitors
650	0	4	_aPurines _xpharmacology
650	0	4	_aQuinazolinones _xpharmacology
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aT-Lymphocytes, Cytotoxic _xdrug effects
650	0	4	_aT-Lymphocytes, Regulatory _xdrug effects
650	0	4	_aTreatment Outcome
700	1		_aCugliandolo, Fiorella M
700	1		_aRosner, Dalya R
700	1		_aGyori, David
700	1		_aRoychoudhuri, Rahul
700	1		_aOkkenhaug, Klaus
773	0		_tJCI insight _gvol. 3 _gno. 11
856	4	0	_uhttps://doi.org/10.1172/jci.insight.120626 _zAvailable from publisher's website
999			_c28503608 _d28503608